| Item type |
文献 / Documents(1) |
| 公開日 |
2022-09-22 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1111/jdi.13899 |
|
|
言語 |
ja |
|
|
関連名称 |
10.1111/jdi.13899 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure : A subanalysis of the randomized CANDLE trial |
|
言語 |
en |
| タイトル別表記 |
|
|
その他のタイトル |
Effects of canagliflozin on WBC counts |
|
言語 |
en |
| 著者 |
タナカ, アツシ
イマイ, タクミ
島袋, 充生
ナカムラ, イクコ
マツナガ, カズオ
オザキ, ユキオ
ミナミノ, トオル
佐田, 政隆
ノデ, コウイチ
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Aims/Introduction: Clinical evidence is lacking about the influence of sodium–glucose cotransporter 2 inhibitors on white blood cell (WBC) counts, a commonly used and widely available marker of inflammation. The aim of the present analysis was to assess the effect of canagliflozin relative to glimepiride on WBC counts.
Materials and Methods: This was a post-hoc subanalysis of the CANDLE trial (Effects of Canagliflozin in Patients with Type 2 Diabetes and Chronic Heart Failure: A Randomized Trial; UMIN000017669), an investigator-initiated, multicenter, open-label, randomized, controlled trial. A total of 233 patients with type 2 diabetes and concomitant heart failure were randomly assigned to either canagliflozin (n = 113) or glimepiride (n = 120) treatment for 24 weeks. Overall, patient baseline characteristics were as follows: mean ± standard deviation age, 68.6 ± 10.1 years; hemoglobin A1c, 7.0 ± 0.9%; left ventricular ejection fraction, 56.7 ± 14.4%; and median N-terminal pro-brain natriuretic peptide, 252 pg/mL (interquartile range 96–563 pg/mL). The mean baseline WBC counts were 6704 cells/μL (95% confidence interval 6,362–7,047) in the canagliflozin group and 6322 cells/μL (95% confidence interval 5,991–6,654) in the glimepiride group. There were no significant differences between treatment groups in terms of changes in WBC counts from baseline to weeks 4 and 12. In contrast, a group difference (canagliflozin minus glimepiride) from baseline to week 24 was significant (mean difference − 456 cells/μL [95% confidence interval −774 to −139, P = 0.005]).
Conclusions: Our findings suggest that 24 weeks of treatment with canagliflozin, relative to glimepiride, reduced WBC counts in patients with type 2 diabetes and heart failure. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Chronic heart failure |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Sodium–glucose cotransporter 2 inhibitor |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
White blood cell |
| 書誌情報 |
en : Journal of Diabetes Investigation
巻 13,
号 12,
p. 1990-1999,
発行日 2022-09-16
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
20401124 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12488319 |
| 出版者 |
|
|
出版者 |
Asian Association for the Study of Diabetes |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
John Wiley & Sons |
|
言語 |
en |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| EID |
|
|
識別子 |
392132 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
jdi_13_12_1990.pdf (651 KB)
.png)
